Drug intelligence / Profile preview

HRS-7249

Development stage: Phase 2
Lead developer: Suncadia Pharmaceuticals
Modality: Drug Delivery Systems
Administration: Subcutaneous

Overview

HRS-7249 is an investigational antihyperlipidemic drug currently in phase 1 clinical trials for the treatment of hyperlipidemia. It was initially developed by Shanghai Tuojie Biotechnology and is now being developed by Fujian Shengdi Pharmaceutical, a subsidiary of Jiangsu Hengrui Medicine. The drug is administered as a subcutaneous injection and has demonstrated effective and durable triglyceride-lowering effects in non-clinical studies, with good safety and low off-target risk. Its precise mechanism of action has not been disclosed or defined publicly. There are no similar approved products on the market domestically or internationally[1][2][7].

Other names: HRS 7249HRS7249HRS-7249

Targets

ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on HRS-7249.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-7249.

Explore the full profile